Safety and effects of SGLT-2 inhibitor use among LVAD patients with type 2 diabetes mellitus

Matthew Cagliostro; Prabhjot Hundal; Peter Ting; Sonika Patel; Sangita Sudarshan; Jordan Thomas; Kathleen Morris; Donna M. Mancini; Noah Moss; Anuradha Lala; Ashwin Ravichandran; Sumeet S. Mitter

doi:10.1016/j.ahjo.2022.100154

Safety and effects of SGLT-2 inhibitor use among LVAD patients with type 2 diabetes mellitus

Matthew Cagliostro, Prabhjot Hundal, Peter Ting, Sonika Patel, Sangita Sudarshan, Jordan Thomas, Kathleen Morris, Donna M. Mancini, Noah Moss, Anuradha Lala, Ashwin Ravichandran, Sumeet S. Mitter

Research output: Contribution to journal › Article › peer-review

7 Scopus citations

Abstract

SGLT-2 inhibitors have been shown to confer reduced risk of adverse cardiovascular events in patients with heart failure, and have also been studied preliminarily among heart transplant patients, with overall positive findings. Use of SGLT-2 inhibitors among patients with durable mechanical circulatory support has not been studied. Here we present our results from a combined retrospective cohort of LVAD patients on SGLT-2 inhibitors at two major academic centers, which showed a good safety profile but prompted questions for further investigation. We advocate for further research into the safety and impact of SGLT-2 inhibitors among LVAD patients.

Original language	English
Article number	100154
Journal	American Heart Journal Plus: Cardiology Research and Practice
Volume	18
DOIs	https://doi.org/10.1016/j.ahjo.2022.100154
State	Published - Jun 2022

Keywords

Heart failure
Left ventricular assist device (LVAD)
SGLT2 inhibitors (SGLT2i)

Access to Document

10.1016/j.ahjo.2022.100154

Cite this

Cagliostro, M., Hundal, P., Ting, P., Patel, S., Sudarshan, S., Thomas, J., Morris, K., Mancini, D. M., Moss, N., Lala, A., Ravichandran, A., & Mitter, S. S. (2022). Safety and effects of SGLT-2 inhibitor use among LVAD patients with type 2 diabetes mellitus. American Heart Journal Plus: Cardiology Research and Practice, 18, Article 100154. https://doi.org/10.1016/j.ahjo.2022.100154

@article{18c098b11ed8484cb7730a7ac0deb964,

title = "Safety and effects of SGLT-2 inhibitor use among LVAD patients with type 2 diabetes mellitus",

abstract = "SGLT-2 inhibitors have been shown to confer reduced risk of adverse cardiovascular events in patients with heart failure, and have also been studied preliminarily among heart transplant patients, with overall positive findings. Use of SGLT-2 inhibitors among patients with durable mechanical circulatory support has not been studied. Here we present our results from a combined retrospective cohort of LVAD patients on SGLT-2 inhibitors at two major academic centers, which showed a good safety profile but prompted questions for further investigation. We advocate for further research into the safety and impact of SGLT-2 inhibitors among LVAD patients.",

keywords = "Heart failure, Left ventricular assist device (LVAD), SGLT2 inhibitors (SGLT2i)",

author = "Matthew Cagliostro and Prabhjot Hundal and Peter Ting and Sonika Patel and Sangita Sudarshan and Jordan Thomas and Kathleen Morris and Mancini, {Donna M.} and Noah Moss and Anuradha Lala and Ashwin Ravichandran and Mitter, {Sumeet S.}",

note = "Publisher Copyright: {\textcopyright} 2022 The Authors",

year = "2022",

month = jun,

doi = "10.1016/j.ahjo.2022.100154",

language = "English",

volume = "18",

journal = "American Heart Journal Plus: Cardiology Research and Practice",

issn = "2666-6022",

publisher = "Elsevier Inc.",

}

TY - JOUR

T1 - Safety and effects of SGLT-2 inhibitor use among LVAD patients with type 2 diabetes mellitus

AU - Cagliostro, Matthew

AU - Hundal, Prabhjot

AU - Ting, Peter

AU - Patel, Sonika

AU - Sudarshan, Sangita

AU - Thomas, Jordan

AU - Morris, Kathleen

AU - Mancini, Donna M.

AU - Moss, Noah

AU - Lala, Anuradha

AU - Ravichandran, Ashwin

AU - Mitter, Sumeet S.

PY - 2022/6

Y1 - 2022/6

N2 - SGLT-2 inhibitors have been shown to confer reduced risk of adverse cardiovascular events in patients with heart failure, and have also been studied preliminarily among heart transplant patients, with overall positive findings. Use of SGLT-2 inhibitors among patients with durable mechanical circulatory support has not been studied. Here we present our results from a combined retrospective cohort of LVAD patients on SGLT-2 inhibitors at two major academic centers, which showed a good safety profile but prompted questions for further investigation. We advocate for further research into the safety and impact of SGLT-2 inhibitors among LVAD patients.

AB - SGLT-2 inhibitors have been shown to confer reduced risk of adverse cardiovascular events in patients with heart failure, and have also been studied preliminarily among heart transplant patients, with overall positive findings. Use of SGLT-2 inhibitors among patients with durable mechanical circulatory support has not been studied. Here we present our results from a combined retrospective cohort of LVAD patients on SGLT-2 inhibitors at two major academic centers, which showed a good safety profile but prompted questions for further investigation. We advocate for further research into the safety and impact of SGLT-2 inhibitors among LVAD patients.

KW - Heart failure

KW - Left ventricular assist device (LVAD)

KW - SGLT2 inhibitors (SGLT2i)

UR - http://www.scopus.com/inward/record.url?scp=85153881014&partnerID=8YFLogxK

U2 - 10.1016/j.ahjo.2022.100154

DO - 10.1016/j.ahjo.2022.100154

M3 - Article

AN - SCOPUS:85153881014

SN - 2666-6022

VL - 18

JO - American Heart Journal Plus: Cardiology Research and Practice

JF - American Heart Journal Plus: Cardiology Research and Practice

M1 - 100154

ER -

Safety and effects of SGLT-2 inhibitor use among LVAD patients with type 2 diabetes mellitus

Abstract

Keywords

Access to Document

Fingerprint

Cite this